These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 16582508

  • 1. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
    Takahashi S.
    Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
    [Abstract] [Full Text] [Related]

  • 2. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M, Yonese J, Fukui I, Ogata E.
    J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
    [Abstract] [Full Text] [Related]

  • 3. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M, Takahashi S, Ogata E.
    Anticancer Res; 2003 Apr; 23(5b):4095-9. PubMed ID: 14666607
    [Abstract] [Full Text] [Related]

  • 4. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Apr; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 5. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y, Ochi M, Tokue A.
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [Abstract] [Full Text] [Related]

  • 6. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
    Ueda M, Inaba M, Okuno S, Maeno Y, Ishimura E, Yamakawa T, Nishizawa Y.
    Life Sci; 2005 Jul 22; 77(10):1130-9. PubMed ID: 15978265
    [Abstract] [Full Text] [Related]

  • 7. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M, Noda S.
    J Urol; 2001 Sep 22; 166(3):1106-10. PubMed ID: 11490307
    [Abstract] [Full Text] [Related]

  • 8. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
    Francini G, Gonnelli S, Petrioli R, Bruni S, Marsili S, Aquino A, Camporeale A.
    Cancer Epidemiol Biomarkers Prev; 1993 Sep 22; 2(2):125-9. PubMed ID: 8467247
    [Abstract] [Full Text] [Related]

  • 9. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE.
    J Natl Cancer Inst; 2005 Jan 05; 97(1):59-69. PubMed ID: 15632381
    [Abstract] [Full Text] [Related]

  • 10. Bone markers in osteoporosis and malignancy.
    Lipton A, Costa L, Demers LM.
    Can J Oncol; 1995 Dec 05; 5 Suppl 1():11-5. PubMed ID: 8853519
    [Abstract] [Full Text] [Related]

  • 11. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
    DeLaurier A, Jackson B, Pfeiffer D, Ingham K, Horton MA, Price JS.
    Res Vet Sci; 2004 Aug 05; 77(1):29-39. PubMed ID: 15120950
    [Abstract] [Full Text] [Related]

  • 12. Assessment of four biochemical markers of bone metabolism in postmenopausal osteoporosis.
    Majkić-Singh N, Ilić M, Ignjatović S, Aleksandra-Postić-Grujin.
    Clin Lab; 2002 Aug 05; 48(7-8):407-13. PubMed ID: 12146575
    [Abstract] [Full Text] [Related]

  • 13. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
    Igawa T, Sakai H, Kanetake H, Saito Y.
    Hinyokika Kiyo; 1999 Apr 05; 45(4):235-9. PubMed ID: 10363141
    [Abstract] [Full Text] [Related]

  • 14. [Biochemical bone turnover markers in patients with conventional and nonconventional osteosarcoma].
    Ambroszkiewicz J, Gajewska J, Klepacka T, Bilska K, Woźniak W, Laskowska-Klita T.
    Pol Merkur Lekarski; 2006 Oct 05; 21(124):330-4. PubMed ID: 17205770
    [Abstract] [Full Text] [Related]

  • 15. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
    Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriguchi A, Nishizawa Y.
    J Bone Miner Metab; 2004 Oct 05; 22(2):127-31. PubMed ID: 14999523
    [Abstract] [Full Text] [Related]

  • 16. Biological variability in serum and urinary indices of bone formation and resorption in dogs.
    Ladlow JF, Hoffmann WE, Breur GJ, Richardson DC, Allen MJ.
    Calcif Tissue Int; 2002 Mar 05; 70(3):186-93. PubMed ID: 11907716
    [Abstract] [Full Text] [Related]

  • 17. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
    Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD.
    Br J Cancer; 2000 Feb 05; 82(4):858-64. PubMed ID: 10732759
    [Abstract] [Full Text] [Related]

  • 18. Biochemical markers of bone turnover: an update.
    van Daele PL, Birkenhäger JC, Pols HA.
    Neth J Med; 1994 Feb 05; 44(2):65-72. PubMed ID: 8208326
    [Abstract] [Full Text] [Related]

  • 19. Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma.
    Kowalska M, Druzd-Sitek A, Fuksiewicz M, Kotowicz B, Chechlinska M, Syczewska M, Walewski J, Kaminska J.
    Clin Biochem; 2010 Apr 05; 43(6):604-8. PubMed ID: 20045402
    [Abstract] [Full Text] [Related]

  • 20. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
    Kanakis I, Nikolaou M, Pectasides D, Kiamouris C, Karamanos NK.
    J Pharm Biomed Anal; 2004 Mar 01; 34(4):827-32. PubMed ID: 15019061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.